At a health-focused event in New York on Tuesday, Google announced that it is developing a series of “open” AI-type models called TXGEMMA.
Google said AI model will be released through it Health AI Developer Foundation According to the company, plans later this month can understand the structure of “regular texts” and different “therapeutic entities”, including chemicals, molecules and proteins.
“The development of therapeutic drugs from concept to approved use is a long and expensive process, so we are working with the wider research community to find new ways to increase the efficiency of this development,” Karen Desalvo, chief health officer of Google, wrote in a blog post providing TechCrunch.[R]Researchers can ask TXGEMMA questions to help predict important properties of potential new therapies, such as their safety or effectiveness. ”
Google didn’t say whether the license for the model allows commercial use, customization or fine-tuning. TechCrunch contacts the company for more information and will be updated if the company responds.
Countless companies, including Google clips Isomorphic Laboratoryit has been guaranteed that AI can one day revolutionize drug discovery by significantly accelerating the earliest R&D steps. Despite some success, AI does not provide a direct and magical solution in the lab.
Several companies that employ AI for drug discovery, including Exscientia and Benevolentaisuffered Highly watched Clinical trial failed In recent years. Meanwhile, lead the accuracy of drug discovery in AI systems, such as Google Deepmind Alphafold 3,,,,, Often very different.
Nevertheless, big pharma companies and investors seem to be passionate about the potential of technology. In January, isomorphism, which has a partnership with pharmaceutical giants Eli Lilly and Novartis, said it hopes to test its AI-designed drugs sometime this year. one estimateMore than 460 AI startups are studying drug discovery, and Investors poured So far, the space has cost $60 billion.
